miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2

Abstract

In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level. Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2), and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay to test the inhibition effect of miR-122 ASO therapy against hepatocarcinoma. miR-122 was reduced in hepatocarcinoma tissues compared to the paracarcinoma tissues, which was relatively low or high in hepatocarcinoma cell line SMMC7721 or Hep3B, and overexpressed miR-122 inhibited proliferation, migration, and invasion in hepatocarcinoma cells. Additionally, some reports showed that LMNB2 was regulated by miR-122, which inhibited the expression of LMNB2. Moreover, LMNB2 functioned to promote cell proliferation, migration, and invasion. We could achieve the inhibition of hepatocarcinoma using miR-122 therapy through decreasing LMNB2 expression in vivo. Our data indicated that miR-122 could inhibit hepatocellular carcinoma cell progression by targeting LMNB2 and as a therapeutic target for hepatocarcinoma treatment.

Lamin B2 promotes the progression of triple negative breast cancer via mediating cell proliferation and apoptosis

“…LMNB2 is a nuclear lamin protein and may be one of the intra-nuclear targets [12]. It was reported that microRNA-122 inhibits HCC cell progression via targeting LMNB2 [26]. LMNB2 was also found to be significantly related with NSCLC progression [22].…”

LMNB2 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma

“…7 An in vitro study was conducted, which identified LMNB2 as a novel downstream target of miR-122 in promoting liver cancer. 13 However, the role of LMNB2 in HCC remains unclear.…”

“…A previous study revealed that increased lamin B2 expression was associated with advanced clinicopathological characteristics of NSCLC, and that lamin B2 enhanced NSCLC occurrence and progression by interacting with the minichromosome maintenance complex component 7 7 . An in vitro study was conducted, which identified LMNB2 as a novel downstream target of miR‐122 in promoting liver cancer 13 . However, the role of LMNB2 in HCC remains unclear.…”

Exosome in Hepatocellular Carcinoma: an update

“…On the one hand, the tumor suppressor contained in the exosomes can directly exhibit tumor suppression effects. For example, studies have shown that exosomal miR-122 produced by hepatocellular carcinoma can inhibit EMT, increase drug sensitivity, and inhibit angiogenesis by targeting LMNB2 [83,84]. On the other hand, because exosomes are lipid-like and easy to metastasize, their stable membrane structure is certainly an advantage for the stability of such vehicles following intravenous injection.…”